KalVista Pharmaceuticals (KALV) Equity Average (2016 - 2024)
Historic Equity Average for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q4 2024 value amounting to $149.2 million.
- KalVista Pharmaceuticals' Equity Average changed N/A to $149.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $149.2 million, marking a year-over-year change of. This contributed to the annual value of $90.2 million for FY2020, which is 4556.7% up from last year.
- Per KalVista Pharmaceuticals' latest filing, its Equity Average stood at $149.2 million for Q4 2024.
- KalVista Pharmaceuticals' 5-year Equity Average high stood at $189.7 million for Q3 2024, and its period low was $61.8 million during Q1 2021.
- For the 4-year period, KalVista Pharmaceuticals' Equity Average averaged around $113.2 million, with its median value being $100.2 million (2023).
- In the last 5 years, KalVista Pharmaceuticals' Equity Average crashed by 3412.13% in 2021 and then skyrocketed by 9170.34% in 2024.
- Over the past 4 years, KalVista Pharmaceuticals' Equity Average (Quarter) stood at $69.7 million in 2020, then dropped by 11.38% to $61.8 million in 2021, then skyrocketed by 105.42% to $126.9 million in 2023, then grew by 17.56% to $149.2 million in 2024.
- Its Equity Average stands at $149.2 million for Q4 2024, versus $153.4 million for Q4 2024 and $189.7 million for Q3 2024.